{"nctId":"NCT02607618","briefTitle":"Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-2","startDateStruct":{"date":"2015-11"},"conditions":["Skin Structures and Soft Tissue Infections"],"count":613,"armGroups":[{"label":"iclaprim","type":"EXPERIMENTAL","interventionNames":["Drug: Iclaprim"]},{"label":"vancomycin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Vancomycin"]}],"interventions":[{"name":"Iclaprim","otherNames":["MTF-100"]},{"name":"Vancomycin","otherNames":["Vancocin"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. written informed consent;\n2. ≥18 years of age;\n3. a bacterial infection of the skin with a lesion size area of at least 75 cm2;\n4. a major cutaneous abscess, cellulitis/erysipelas, and/or wound infections;\n5. the presence of purulent or seropurulent drainage or at least three signs and symptoms of infection (discharge, erythema, swelling, warmth, or pain).\n\nExclusion Criteria:\n\n1. severely impaired arterial blood supply such that amputation of the infected anatomical site is likely;\n2. infected diabetic foot ulcers;\n3. infected decubitus ulcers;\n4. necrotizing fasciitis or gangrene;\n5. uncomplicated skin or skin structure infection;\n6. infections associated with a prosthetic device;\n7. suspected or confirmed osteomyelitis;\n8. conditions requiring systemic anti-microbial treatment, prophylaxis, or suppression therapy.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent of Participants With ≥20% Reduction in Lesion Size at 48 to 72 Hours Compared to Baseline","description":"≥20% reduction in lesion size at 48 to 72 hours (Early Time Point \\[ETP\\]) compared to baseline in all randomized patients (ITT).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78.3","spread":null},{"groupId":"OG001","value":"76.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Resolution or Near Resolution of Lesion at Test of Cure Visit","description":"Resolution or Near Resolution of Lesion at Test of Cure (TOC) Visit.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"229","spread":null},{"groupId":"OG001","value":"237","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":299},"commonTop":["Product Issues"]}}}